With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX ... Vertex has diversified ...

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $451 from $437 but keeps a Sector Perform rating on the ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle ... in both CF and the early launch of CASGEVY, as well as launch preparedness for ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Nov 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new ... CF treatments as well as for the launch of its gene therapy, Casgevy, in approved indications and geographies, the company said.